133 related articles for article (PubMed ID: 6377080)
1. A microautomated dilution method for susceptibility testing with antifungal drugs.
Polonelli L; Morace G
Mycopathologia; 1984 Apr; 86(1):21-8. PubMed ID: 6377080
[TBL] [Abstract][Full Text] [Related]
2. Antifungal susceptibility testing using the E test: comparison with the broth macrodilution technique.
Chen SC; O'Donnell ML; Gordon S; Gilbert GL
J Antimicrob Chemother; 1996 Feb; 37(2):265-73. PubMed ID: 8707736
[TBL] [Abstract][Full Text] [Related]
3. Antifungal susceptibility testing of yeast isolates from blood cultures by microbroth dilution and the E test.
Simor AE; Goswell G; Louie L; Lee M; Louie M
Eur J Clin Microbiol Infect Dis; 1997 Sep; 16(9):693-7. PubMed ID: 9352266
[TBL] [Abstract][Full Text] [Related]
4. In vitro susceptibility of 119 yeast isolates to fluconazole, 5-fluorocytosine, amphotericin B and ketoconazole.
Morace G; Manzara S; Dettori G
Chemotherapy; 1991; 37(1):23-31. PubMed ID: 2013239
[TBL] [Abstract][Full Text] [Related]
5. Multi-centre evaluation of the Etest method for antifungal drug susceptibility testing of Candida spp. and Cryptococcus neoformans. BSAC Working Party on Antifungal Chemotherapy.
Warnock DW; Johnson EM; Rogers TR
J Antimicrob Chemother; 1998 Sep; 42(3):321-31. PubMed ID: 9786472
[TBL] [Abstract][Full Text] [Related]
6. Development of reference procedures for broth microdilution antifungal susceptibility testing of yeasts with standardized endpoint determination.
Makimura K; Sudo T; Kudo M; Uchida K; Yamaguchi H
Microbiol Immunol; 1998; 42(1):55-9. PubMed ID: 9525781
[TBL] [Abstract][Full Text] [Related]
7. Itraconazole vs amphotericin B: in vitro comparative evaluation of the minimal inhibitory concentration (MIC) against clinically isolated yeasts.
Lombardi G; Gramegna G; Cavanna C; Poma G; Marangoni E; Michelone G
Mycopathologia; 1989 Apr; 106(1):31-4. PubMed ID: 2549421
[TBL] [Abstract][Full Text] [Related]
8. Susceptibility testing of Cryptococcus neoformans using the urea broth microdilution method.
Nakamura Y; Kano R; Watanabe S; Takahashi H; Hasegawa A
Mycoses; 1998; 41(1-2):41-4. PubMed ID: 9610132
[TBL] [Abstract][Full Text] [Related]
9. [Studies on microtiter broth dilution method for antifungal susceptibility testing of yeast isolates from blood and cerebrospinal fluid].
Fujita S
Rinsho Byori; 1996 Apr; 44(4):373-8. PubMed ID: 8847821
[TBL] [Abstract][Full Text] [Related]
10. Clinical evaluation of a dried commercially prepared microdilution panel for antifungal susceptibility testing of five antifungal agents against Candida spp. and Cryptococcus neoformans.
Pfaller MA; Boyken L; Hollis RJ; Messer SA; Tendolkar S; Diekema DJ
Diagn Microbiol Infect Dis; 2004 Oct; 50(2):113-7. PubMed ID: 15474320
[TBL] [Abstract][Full Text] [Related]
11. Modified agar dilution susceptibility testing method for determining in vitro activities of antifungal agents, including azole compounds.
Yoshida T; Jono K; Okonogi K
Antimicrob Agents Chemother; 1997 Jun; 41(6):1349-51. PubMed ID: 9174197
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Etest method for determining isavuconazole MICs against Cryptococcus gattii and Cryptococcus neoformans.
Thompson GR; Fothergill AW; Wiederhold NP; Vallor AC; Wickes BL; Patterson TF
Antimicrob Agents Chemother; 2008 Aug; 52(8):2959-61. PubMed ID: 18559645
[TBL] [Abstract][Full Text] [Related]
13. Influence of culture medium on susceptibility testing with BAY n 7133 and ketoconazole.
Hoeprich PD; Merry JM
J Clin Microbiol; 1986 Aug; 24(2):269-71. PubMed ID: 3528213
[TBL] [Abstract][Full Text] [Related]
14. In vitro susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species to itraconazole: global survey of 9,359 isolates tested by clinical and laboratory standards institute broth microdilution methods.
Pfaller MA; Boyken L; Hollis RJ; Messer SA; Tendolkar S; Diekema DJ
J Clin Microbiol; 2005 Aug; 43(8):3807-10. PubMed ID: 16081915
[TBL] [Abstract][Full Text] [Related]
15. In vitro activities of posaconazole (Sch 56592) compared with those of itraconazole and fluconazole against 3,685 clinical isolates of Candida spp. and Cryptococcus neoformans.
Pfaller MA; Messer SA; Hollis RJ; Jones RN
Antimicrob Agents Chemother; 2001 Oct; 45(10):2862-4. PubMed ID: 11557481
[TBL] [Abstract][Full Text] [Related]
16. In-vitro activity of dicationic aromatic compounds and fluconazole against Cryptococcus neoformans and Candida spp.
Del Poeta M; Bixel AS; Barchiesi F; Tidwell RR; Boykin D; Scalise G; Perfect JR
J Antimicrob Chemother; 1999 Aug; 44(2):223-8. PubMed ID: 10473229
[TBL] [Abstract][Full Text] [Related]
17. Comparison of a new commercial colorimetric microdilution method with a standard method for in-vitro susceptibility testing of Candida spp. and Cryptococcus neoformans.
Davey KG; Szekely A; Johnson EM; Warnock DW
J Antimicrob Chemother; 1998 Oct; 42(4):439-44. PubMed ID: 9818741
[TBL] [Abstract][Full Text] [Related]
18. Comparative study of antifungal activity of sertaconazole, terbinafine, and bifonazole against clinical isolates of Candida spp., Cryptococcus neoformans and dermatophytes.
Carillo-Muñoz AJ; Tur-Tur C
Chemotherapy; 1997; 43(6):387-92. PubMed ID: 9395851
[TBL] [Abstract][Full Text] [Related]
19. In vitro antifungal activities of Bay n 7133 and Bay L 9139, two new orally absorbed antifungal imidazole derivatives, against pathogenic yeasts.
Fromtling RA; Yu HP; Shadomy S
Mycopathologia; 1984 Apr; 86(1):45-50. PubMed ID: 6330557
[TBL] [Abstract][Full Text] [Related]
20. Two-site comparison of broth microdilution and semisolid agar dilution methods for susceptibility testing of Cryptococcus neoformans in three media.
Anaissie E; Shawar R; Paetznick V; Ensign LG; Witte Z; LaRocco M
J Clin Microbiol; 1993 May; 31(5):1370-2. PubMed ID: 8501245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
